Novadip is a brand committed to providing innovative regenerative medicine solutions for patients with limited or no effective treatment options. Founded in 2013 as a spin-off company from Université Catholique de Louvain and St. Luc University Hospital, Novadip is focused on addressing the challenges of large bone defects, bone non-union, and spine fusion.

The brand's mission is to develop a new class of regenerative tissue products that accelerate healing in a single treatment. Novadip's unique 3M3 tissue regeneration platform leverages adipose-derived stem cells within a three-dimensional extracellular matrix, based on the scientific discoveries of founder Dr. Denis Dufrane.

This platform has resulted in the creation of 15 procedures for bone reconstruction and 7 implantations for skin regeneration. With a team of 45 experts and a deep knowledge of science, regulation, and development pathways, Novadip is advancing the standard of care in bone and tissue regenerative medicine. The brand is driven by a passion to restore mobility, avoid amputations, and improve the quality of life for patients